CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

Maeva Dufies, Sandy Giuliano, Julien Viotti, Delphine Borchiellini, Linsay S. Cooley, Damien Ambrosetti, Mélanie Guyot, Papa Diogop Ndiaye, Julien Parola, Audrey Claren, Renaud Schiappa, Jocelyn Gal, Antoine Frangeul, Arnaud Jacquel, Ophélie Cassuto, Renaud Grépin, Patrick Auberger, Andréas Bikfalvi, Gérard Milano, Bernard EscudierNathalie Rioux-Leclercq, Camillo Porta, Sylvie Negrier, Emmanuel Chamorey, Jean Marc Ferrero, Gilles Pagès

Research output: Contribution to journalArticlepeer-review


Background:Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective is to discover predictive markers of response to adapt the treatment at diagnosis.Methods:Prospective phase 2 multi-centre trials were conducted in ccRCC patients initiating sunitinib (54 patients) or bevacizumab (45 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials). The plasmatic level of CXCL7 at baseline was correlated with progression-free survival (PFS).Results:The cut-off value of CXCL7 for PFS was 250 ng ml-1. Patients with CXCL7 plasmatic levels above the cut-off at baseline (250 ng ml-1) had a significantly longer PFS (hazard ratio 0.323 (95% confidence interval 0.147-0.707), P=0.001). These results were confirmed in a retrospective validation cohort. The levels of CXCL7 did not influence PFS of the bevacizumab-treated patients.Conclusions:CXCL7 may be considered as a predictive marker of sunitinib efficacy for ccRCC patients.

Original languageEnglish
Pages (from-to)947-953
Number of pages7
JournalBritish Journal of Cancer
Issue number7
Publication statusPublished - Sep 26 2017


  • ccRCC
  • CXCL7
  • plasma
  • predictive marker
  • sunitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas'. Together they form a unique fingerprint.

Cite this